Noninvasive Imaging in CD

CE / CME

Interactive Case Challenge 2: Integrating Noninvasive Imaging in Crohn’s Disease Management 

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Released: March 20, 2025

Expiration: March 19, 2026

Activity

Progress
1 2
Course Completed

Case History


 
The findings of Mr Burns’ MRE suggest ongoing inflammation, which correlates with his elevated CRP (12 mg/L) and fecal calprotectin (450 µg/g). The mild narrowing could indicate early fibrotic changes but is not yet causing a clinically significant obstruction. Mr Burns is brought in to discuss these results. Given his current therapy with infliximab (5 mg/kg every 8 weeks) and azathioprine (150 mg/day), additional testing was required to evaluate treatment efficacy. 


He is sent for further lab evaluation, which revealed an infliximab trough level of 1.5 µg/mL with no antidrug antibodies.  

What would be the most appropriate next step in management for this patient?